Inhibrx Biosciences (INBX) Invested Capital (2023 - 2025)
Historic Invested Capital for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $136.7 million.
- Inhibrx Biosciences' Invested Capital fell 2337.69% to $136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.7 million, marking a year-over-year decrease of 2337.69%. This contributed to the annual value of $133.6 million for FY2024, which is 20706.85% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Invested Capital is $136.7 million, which was down 2337.69% from $167.8 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Invested Capital peaked at $219.4 million during Q2 2024, and registered a low of $43.5 million during Q4 2023.
- In the last 3 years, Inhibrx Biosciences' Invested Capital had a median value of $167.8 million in 2025 and averaged $153.2 million.
- In the last 5 years, Inhibrx Biosciences' Invested Capital soared by 20706.85% in 2024 and then plummeted by 2348.95% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Invested Capital stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024, then increased by 2.37% to $136.7 million in 2025.
- Its last three reported values are $136.7 million in Q3 2025, $167.8 million for Q2 2025, and $193.1 million during Q1 2025.